Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 11.
doi: 10.1002/ejhf.3795. Online ahead of print.

Rationale and design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) trial

Thomas J Stocker  1   2 , Tobias Geisler  3 , Wolfgang Rottbauer  4 , Edith Lubos  5 , Christian Frerker  6   7 , Niklas Schofer  7   8 , Johanne Frank  7   9 , Ralph Stephan von Bardeleben  10   11 , Tobias Kister  12 , Rico Osteresch  13 , Alexander Lauten  14 , Tienush Rassaf  15 , Jürgen Rothe  16 , David M Leistner  11   17 , Lukas Stolz  1   2 , Victoria Kehl  18 , Maria Grzeschniok  18 , Andreas Hagendorff  19 , Volker Rudolph  20 , Stephan Baldus  21 , Philipp Lurz  10   11 , Steffen Massberg  1   2 , Jörg Hausleiter  1   2 ; TRIC‐I‐HF‐DZHK24 Investigators
Collaborators, Affiliations

Rationale and design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) trial

Thomas J Stocker et al. Eur J Heart Fail. .

Abstract

Aims: Tricuspid regurgitation (TR) is a detrimental disease frequently diagnosed in patients with right-sided heart failure (HF). While transcatheter tricuspid valve interventions (TTVI) effectively reduce TR and improve quality of life (QoL) in earlier stages of the disease, their effect on reducing HF hospitalizations (HFH) and improving survival remains unclear.

Methods: TRIC-I-HF-DZHK24 (NCT04634266) is an investigator-initiated, prospective, randomized, open-label, multicentre strategy trial. Approximately 360 patients with severe TR and manifest right-sided HF will be enrolled. In contrast to previous trials, subjects with increased risk for HFH will be selected as facilitated by specific inclusion criteria: HFH in the previous year, or presence of cardio-renal syndrome, or evidence for cardio-hepatic syndrome. Subjects will be randomized 2:1 to TTVI and optimal medical therapy (OMT) or continuation of OMT alone. All CE-marked transcatheter repair devices including tricuspid transcatheter edge-to-edge repair (T-TEER) or transcatheter tricuspid annuloplasty can be used for TTVI. The participating 29 study sites are highly experienced and treated a mean of 176 patients in 4.5 years with T-TEER before study activation. The primary outcome will be assessed at 1 year. First, a composite of all-cause mortality, HFH, and QoL improvement will be tested hierarchically. If positive, the combination of hard clinical endpoints including all-cause mortality and HFH will be tested. Patients will be followed for a total of 3 years. The safety outcome comprises complications of TTVI, life-threatening bleeding and death.

Conclusions: The TRIC-I-HF-DZHK24 trial will define the role of TTVI in patients with severe TR and right-sided HF.

Keywords: Heart failure; Manifest right‐sided heart failure; Optimal medical therapy; Transcatheter tricuspid valve intervention; Tricuspid regurgitation; Tricuspid transcatheter edge‐to‐edge repair.

PubMed Disclaimer

References

    1. Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 2019;12:433–442. https://doi.org/10.1016/j.jcmg.2018.06.014
    1. Wang N, Fulcher J, Abeysuriya N, McGrady M, Wilcox I, Celermajer D, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: A systematic review and meta‐analysis. Eur Heart J 2019;40:476–484. https://doi.org/10.1093/eurheartj/ehy641
    1. Dreyfus J, Flagiello M, Bazire B, Eggenspieler F, Viau F, Riant E, et al. Isolated tricuspid valve surgery: Impact of aetiology and clinical presentation on outcomes. Eur Heart J 2020;41:4304–4317. https://doi.org/10.1093/eurheartj/ehaa643
    1. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561–632. https://doi.org/10.1093/eurheartj/ehab395
    1. Lurz P, Rommel KP, Schmitz T, Bekeredjian R, Nickenig G, Möllmann H, et al. Real‐world 1‐year results of tricuspid edge‐to‐edge repair from the bRIGHT study. J Am Coll Cardiol 2024;84:607–616. https://doi.org/10.1016/j.jacc.2024.05.006

LinkOut - more resources